Since its spin-off from Kiel University in 2025, Germany, QuantView has been conducting applied research with numerous renowned research partners in Germany and abroad on the practical further development of Metabolic Resonance Imaging.

We are using our own patented, advanced “PHIP plus” technique instead of the less powerful “PHIP” technique where “PHIP” stands for “parahydrogen-induced polarization”.

The aim is to use our method to detect cancer recognise cancer at an extremely early stage, at best when a single cancer cell has just developed.

We are based in the Kiel Science Park right next to the University Campus, Department of Chemistry, so that we have short distances to the laboratories there, which we can use within the framework of licence agreements.

Our team is interdisciplinary and heterogeneous and consists of experienced chemists, physicists, entrepreneurs, business economists, finance and marketing experts.

We pool our knowledge together and want to use our unique diagnostic procedure to help prevent one of the most widespread disease, cancer.

From Publication to Patent: Pioneering the Future of Hyperpolarized Imaging

Our team is proud to be at the forefront of the highly innovativ field of metabolic imaging using hyperpolarized pyruvate.

Our leadership in the area is exemplified by our flagship publication, in which we achieved a breakthrough in the synthesis of the hyperpolarizable contrast agent vinyl pyruvate — a compound that plays a key role in shaping the future of this imaging technique and firmly positions us as leaders in this field.